RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000077.xml
PDF herunterladen
Semin Thromb Hemost
DOI: 10.1055/s-0045-1810021
DOI: 10.1055/s-0045-1810021
Editorial
Seminars in Thrombosis and Hemostasis: 2024 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics
This Editorial continues the now standard approach to announce the newest Seminars in Thrombosis and Hemostasis (STH) Journal Impact Factor (IF) and other journal metrics, upon release of the latest IF.[1] [2] [3] [4]
Publikationsverlauf
Artikel online veröffentlicht:
09. Juli 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Favaloro EJ. New STH (2020) impact factor, most highly cited papers, and other journal metrics. Semin Thromb Hemost 2021; 47 (07) 745-753
- 2 Favaloro EJ. New Seminars in Thrombosis and Hemostasis (STH) 2021 impact factor, most highly cited papers, and other journal metrics. Semin Thromb Hemost 2022; 48 (06) 634-642
- 3 Favaloro EJ. New Seminars in Thrombosis and Hemostasis 2022 impact factor, most highly cited papers, and other journal metrics. Semin Thromb Hemost 2023; 49 (07) 661-669
- 4 Favaloro EJ. New STH 2023 impact factor, most highly cited papers, and other journal metrics. Semin Thromb Hemost 2024; 50 (08) 1058-1066
- 5 WHO. COVID-19 dashboard. Accessed June 21, 2025 at: https://data.who.int/dashboards/covid19/cases
- 6 COVID-19 vaccination, World data. Accessed June 21, 2025 at: https://data.who.int/dashboards/covid19/vaccines?n=o
- 7 National Library of Medicine/National Center for Biotechnology Information/PubMed.com. Accessed June 21, 2025 at: https://pubmed.ncbi.nlm.nih.gov/?term=COVID-19+or+COVID19+or+SARS-CoV-2&sort=date&size=200
- 8 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part I. Semin Thromb Hemost 2020; 46 (07) 757-762
- 9 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): part II. Semin Thromb Hemost 2021; 47 (04) 333-337
- 10 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part III. Semin Thromb Hemost 2022; 48 (01) 3-7
- 11 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part IV. Semin Thromb Hemost 2023; 49 (01) 3-8
- 12 Favaloro EJ. 2021 Eberhard F. Mammen Award announcements: part I-most popular articles. Semin Thromb Hemost 2021; 47 (05) 467-476
- 13 Favaloro EJ. 2022 Eberhard F. Mammen Award announcements: part I-most popular articles. Semin Thromb Hemost 2022; 48 (05) 502-513
- 14 Favaloro EJ. 2023 Eberhard F. Mammen Award announcements: part I-most popular articles. Semin Thromb Hemost 2023; 49 (05) 417-426
- 15 Favaloro EJ. Eberhard F. Mammen Award announcements: part I-most popular articles. Semin Thromb Hemost 2024; 2024 (Mar): 8 . Epub ahead of print
- 16 Favaloro EJ. The Journal Impact Factor: don't expect its demise any time soon. Clin Chem Lab Med 2009; 47 (11) 1319-1324
- 17 Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. Semin Thromb Hemost 2008; 34 (01) 7-25
- 18 Morrow GB, Mutch NJ. Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Semin Thromb Hemost 2023; 49 (03) 305-313
- 19 Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022; 48 (08) 904-910
- 20 Iba T, Wada H, Levy JH. Platelet activation and thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 55-61
- 21 Hartmann J, Dias JD, Pivalizza EG, Garcia-Tsao G. Thromboelastography-guided therapy enhances patient blood management in cirrhotic patients: a meta-analysis based on randomized controlled trials. Semin Thromb Hemost 2023; 49 (02) 162-172
- 22 Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost 2022; 48 (08) 978-987
- 23 Moore GW. Testing for lupus anticoagulants. Semin Thromb Hemost 2022; 48 (06) 643-660
- 24 Okholm SH, Krog J, Hvas AM. Tranexamic acid and its potential anti-inflammatory effect: a systematic review. Semin Thromb Hemost 2022; 48 (05) 568-595
- 25 Bowyer AE, Gosselin RC. Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments. Semin Thromb Hemost 2023; 49 (06) 609-620
- 26
Thachil J,
Favaloro EJ,
Lippi G.
D-dimers—“normal” levels versus elevated levels due to a range of conditions, including
“D-dimeritis,” inflammation, thromboembolism, disseminated intravascular coagulation,
and COVID-19. Semin Thromb Hemost 2022; 48 (06) 672-679
MissingFormLabel
- 27 Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review. Semin Thromb Hemost 2023; 49 (06) 621-633
- 28 Turner S, Naidoo CA, Usher TJ. et al. Increased levels of inflammatory and endothelial biomarkers in blood of long COVID patients point to thrombotic endothelialitis. Semin Thromb Hemost 2024; 50 (02) 288-294
- 29 Grobbelaar LM, Kruger A, Venter C. et al. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost 2022; 48 (07) 858-868
- 30 Richard M, Celeny D, Neerman-Arbez M. Mutations accounting for congenital fibrinogen disorders: an update. Semin Thromb Hemost 2022; 48 (08) 889-903
- 31 Bartlett R, Arachichilage DJ, Chitlur M. et al. The history of extracorporeal membrane oxygenation and the development of extracorporeal membrane oxygenation anticoagulation. Semin Thromb Hemost 2024; 50 (01) 81-90
- 32 Candeloro M, Schulman S. Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis. Semin Thromb Hemost 2023; 49 (01) 47-54
- 33 Luijten D, de Jong CMM, Ninaber MK, Spruit MA, Huisman MV, Klok FA. Post-pulmonary embolism syndrome and functional outcomes after acute pulmonary embolism. Semin Thromb Hemost 2023; 49 (08) 848-860
- 34 Hu M, Li X, Yang Y. Causal associations between cardiovascular risk factors and venous thromboembolism. Semin Thromb Hemost 2023; 49 (07) 679-687
- 35 Adcock DM, Moore GW, Montalvão SL, Kershaw G, Gosselin RC. Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art. Semin Thromb Hemost 2023; 49 (06) 571-579
- 36
Devreese KMJ.
Solid phase assays for antiphospholipid antibodies. Semin Thromb Hemost 2022; 48 (06)
661-671
MissingFormLabel
- 37 Larsen JB, Hvas AM, Hojbjerg JA. Platelet function testing: update and future directions. Semin Thromb Hemost 2023; 49 (06) 600-608
- 38
Casini A,
Moerloose P,
Neerman-Arbez M.
One hundred years of congenital fibrinogen disorders. Semin Thromb Hemost 2022; 48
(08) 880-888
MissingFormLabel
- 39 Favaloro EJ, Dean E, Arunachalam S. Variable performance of lupus anticoagulant testing: the Australasian/Asia-Pacific experience. Semin Thromb Hemost 2024; 50 (08) 1103-1113
- 40 Mabrouk M, Guessous F, Naya A, Merhi Y, Zaid Y. The pathophysiological role of platelet-derived extracellular vesicles. Semin Thromb Hemost 2023; 49 (03) 279-283
- 41 Ortega-Paz L, Talasaz AH, Sadeghipour P. et al. COVID-19-associated pulmonary embolism: review of the pathophysiology, epidemiology, prevention, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (08) 816-832
- 42 Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost 2023; 49 (05) 444-452
- 43 Bikdeli B, Muriel A, Wang Y. et al; RIETE Investigators. Sex-related differences in patient characteristics, risk factors, and symptomatology in older adults with pulmonary embolism: findings from the SERIOUS-PE Study. Semin Thromb Hemost 2023; 49 (07) 725-735
- 44 Boccatonda A, Balletta M, Vicari S, Hoxha A, Simioni P, Campello E. The journey through the pathogenesis and treatment of venous thromboembolism in inflammatory bowel diseases: a narrative review. Semin Thromb Hemost 2023; 49 (07) 744-755
- 45 Gyldenholm T, Hvas AM, Christensen TD, Larsen JB. Thrombin generation markers as predictors of cancer-associated venous thromboembolism: a systematic review. Semin Thromb Hemost 2024; 50 (03) 384-401
- 46 Shavit-Stein E, Berkowitz S, Gofrit SG, Altman K, Weinberg N, Maggio N. Neurocoagulation from a mechanistic point of view in the central nervous system. Semin Thromb Hemost 2022; 48 (03) 277-287
- 47 Lira AL, Kohs TCL, Moellmer SA, Shatzel JJ, McCarty OJT, Puy C. Substrates, cofactors, and cellular targets of coagulation factor XIa. Semin Thromb Hemost 2024; 50 (07) 962-969
- 48 Radin M, Cecchi I, Arbrile M. et al. Pediatric presentation of antiphospholipid syndrome: a review of recent literature with estimation of local prevalence. Semin Thromb Hemost 2024; 50 (02) 182-187
- 49 George JN. Thrombotic thrombocytopenic purpura: from 1972 to 2022 and beyond. Semin Thromb Hemost 2022; 48 (08) 926-936
- 50 Kearney KJ, Ariëns RAS, Macrae FL. The role of fibrin(ogen) in wound healing and infection control. Semin Thromb Hemost 2022; 48 (02) 174-187
- 51 Schellong S, Ageno W, Casella IB. et al. Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism: RE-COVERY DVT/PE Study. Semin Thromb Hemost 2022; 48 (04) 446-458
- 52 Bahraini M, Dorgalaleh A. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Semin Thromb Hemost 2022; 48 (01) 19-30
- 53 Bor MV, Feddersen S, Pedersen IS, Sidelmann JJ, Kristensen SR. Dysfibrinogenemia-potential impact of genotype on thrombosis or bleeding. Semin Thromb Hemost 2022; 48 (02) 161-173
- 54 Favaloro EJ, Henry BM, Lippi G. Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 2022; 48 (01) 55-71
- 55 Favaloro EJ. Celebrating 50 years of Seminars in Thrombosis and Hemostasis-part I. Semin Thromb Hemost 2022; 48 (08) 871-874
- 56 Favaloro EJ. Celebrating 50 years of Seminars in Thrombosis and Hemostasis-part II. Semin Thromb Hemost 2023; 49 (03) 212-216
- 57 Smock KJ, Gosselin RC. Laboratory diagnostics for thrombosis and hemostasis testing-part II. Semin Thromb Hemost 2023; 49 (06) 569-570
- 58 Smock KJ, Gosselin RC. Laboratory diagnostics for thrombosis and hemostasis testing-part I. Semin Thromb Hemost 2022; 48 (06) 631-633
- 59 Schulman S. Recent advances in thrombosis and hemostasis-part IX. Semin Thromb Hemost 2023; 49 (07) 670-672
- 60 Favaloro EJA. 2018 update on the editorial and publication policy of Seminars in Thrombosis and Hemostasis. Semin Thromb Hemost 2018; 44 (04) 307-311
- 61 Favaloro EJ. A short history of Thrombosis and Hemostasis: part I (40th year celebratory issue). Semin Thromb Hemost 2014; 40 (05) 521-525
- 62 Favaloro EJ. A short history of Thrombosis and Hemostasis: part II (40th year celebratory issue). Semin Thromb Hemost 2014; 40 (08) 826-830
- 63 Favaloro EJ. Celebrating 50 years of Seminars in Thrombosis and Hemostasis-part III. Semin Thromb Hemost 2024; 50 (01) 4-7
- 64 Favaloro EJ. Celebrating 50 years of Seminars in Thrombosis and Hemostasis-part IV. Semin Thromb Hemost 2024; 50 (05) 677-681
- 65 Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930-2008). Semin Thromb Hemost 2008; 34 (08) 703-707